🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

448 results for “RAD” Clear

  1. TEMOZOLOMIDE

    The George Institute

    Diffuse low-grade gliomas

    phase 2 small molecule active

    1 trial

  2. TNG908, TNG908, TNG908, TNG908, MIDAZOLAM

    Tango Therapeutics

    "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

    phase 2 small molecule active

    1 trial

  3. TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE

    Novartis Pharmaceuticals

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

  4. TQC2731 injection

    Shanghai University of Traditional Chinese Medicine

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  5. TQH2722 injection

    Shanghai University of Traditional Chinese Medicine

    Seasonal Allergic Rhinitis

    phase 2 small molecule active

    1 trial

  6. TYRA-300 60mg

    Tyra Biosciences

    Low-grade NMIBC

    phase 2 small molecule active

    1 trial

  7. Tecentriq 1 200 mg concentrate for solution for infusion, Pulmocis 2 mg trousse pour préparation radiopharmaceutique, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  8. Tetrahydrobiopterin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation Enteritis

    phase 2 small molecule active

    1 trial

  9. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial

  10. The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP., BRENSOCATIB, BRENSOCATIB

    Insmed Limited

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  11. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  12. Tislelizumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    ESCC

    phase 2 small molecule active

    1 trial

  13. Topical roflumilast 0.3% foam

    Arcutis Biotherapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  14. Tovorafenib, Tovorafenib

    Lacuna Pharma Pty Ltd

    RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients

    phase 2 small molecule active

    1 trial

  15. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  16. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Obesity

    phase 2 small molecule completed

    1 trial

  17. Traditional Chinese acupuncture

    The University of Hong Kong

    Phonotraumatic Injuries

    phase 2 other active

    1 trial

  18. Traditional fabricated prosthetic socket

    United Therapeutics Europe Ltd

    Amputation

    phase 2 other completed

    1 trial

  19. Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 small molecule active

    1 trial

  20. Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  21. Upadacitinib

    AbbVie

    Hidradenitis Suppurativa (HS)

    phase 2 small molecule completed

    1 trial

  22. VAY736, Placebo Solution for injection or infusion 0 mg/1 mL

    Novartis Pharmaceuticals

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  23. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

    phase 2 mab completed

    1 trial

  24. VLY-686 (Tradipitant)

    Vanda Pharmaceuticals Netherlands B.V.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources